IL320663A - Treatment of immune thrombocytopenia - Google Patents
Treatment of immune thrombocytopeniaInfo
- Publication number
- IL320663A IL320663A IL320663A IL32066325A IL320663A IL 320663 A IL320663 A IL 320663A IL 320663 A IL320663 A IL 320663A IL 32066325 A IL32066325 A IL 32066325A IL 320663 A IL320663 A IL 320663A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- immune thrombocytopenia
- thrombocytopenia
- immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263384049P | 2022-11-16 | 2022-11-16 | |
| US202363481841P | 2023-01-27 | 2023-01-27 | |
| PCT/IB2023/061465 WO2024105549A1 (en) | 2022-11-16 | 2023-11-14 | Treatment of immune thrombocytopenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320663A true IL320663A (en) | 2025-07-01 |
Family
ID=88839111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320663A IL320663A (en) | 2022-11-16 | 2025-05-04 | Treatment of immune thrombocytopenia |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4619026A1 (en) |
| JP (1) | JP2025537796A (en) |
| KR (1) | KR20250108117A (en) |
| CN (1) | CN120265311A (en) |
| IL (1) | IL320663A (en) |
| TW (1) | TW202421196A (en) |
| WO (1) | WO2024105549A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026122561A2 (en) | 2024-12-03 | 2026-06-11 | Otsuka America Pharmaceutical, Inc. | Methods of treating sjögren's disease |
-
2023
- 2023-11-14 JP JP2025528255A patent/JP2025537796A/en active Pending
- 2023-11-14 KR KR1020257019257A patent/KR20250108117A/en active Pending
- 2023-11-14 WO PCT/IB2023/061465 patent/WO2024105549A1/en not_active Ceased
- 2023-11-14 CN CN202380079132.5A patent/CN120265311A/en active Pending
- 2023-11-14 TW TW112143855A patent/TW202421196A/en unknown
- 2023-11-14 EP EP23808904.9A patent/EP4619026A1/en active Pending
-
2025
- 2025-05-04 IL IL320663A patent/IL320663A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025537796A (en) | 2025-11-20 |
| WO2024105549A1 (en) | 2024-05-23 |
| EP4619026A1 (en) | 2025-09-24 |
| KR20250108117A (en) | 2025-07-15 |
| TW202421196A (en) | 2024-06-01 |
| CN120265311A (en) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4525871A4 (en) | Treatment of depression | |
| IL315503A (en) | Methods of treatment | |
| IL320711A (en) | Methods of treatment | |
| GB2595513B (en) | Treatment of infections | |
| GB202201824D0 (en) | Methods of treatment | |
| CA3273323A1 (en) | Treatment of immune thrombocytopenia | |
| GB202201819D0 (en) | Methods of treatment | |
| GB202201825D0 (en) | Methods of treatment | |
| HUE068787T2 (en) | Thermal treatment of components | |
| GB202102257D0 (en) | Treatment of shells | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202307686D0 (en) | Treatment of conditions | |
| GB202206348D0 (en) | Treatment of limb spasticity | |
| IL325944A (en) | Treatment methods | |
| GB202003803D0 (en) | Treatment of limb spasticity | |
| GB202101251D0 (en) | Treatment of conditions | |
| GB202118007D0 (en) | Methods of treatment | |
| GB202118006D0 (en) | Methods of treatment | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202108242D0 (en) | Methods of treatment | |
| GB202108245D0 (en) | Methods of treatment | |
| ZA202005856B (en) | Treatment of infections | |
| GB202502238D0 (en) | Treatment of COVID-19 | |
| GB202413538D0 (en) | Treatment of haematoglobinopathies |